RBC Capital Maintains Sector Perform on Sage Therapeutics, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on Sage Therapeutics and lowers the price target from $26 to $15.
April 26, 2024 | 3:56 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RBC Capital has maintained its Sector Perform rating on Sage Therapeutics but lowered the price target from $26 to $15.
The reduction in price target by RBC Capital suggests a bearish outlook on the stock's short-term price potential, likely due to revised expectations on the company's performance or market conditions. This could lead to a negative investor sentiment and a potential decrease in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100